ଡାରିଡୋରେକ୍ସାଣ୍ଟ

ଡାରିଡୋରେକ୍ସାଣ୍ଟ
Clinical data
Trade names	Quviviq
Synonyms	Nemorexant; ACT-541468
AHFS/Drugs.com	monograph
data	US DailyMed: Daridorexant;
Addiction; liability	Some
Routes of; administration	By mouth
Legal status
Legal status	US: Schedule IV ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	62%
Protein binding	99.7%
Metabolism	Extensive (mainly CYP3A4 (89%))
Onset of action	Tmax: 1–2 hours (delayed by 1.3 hours with food)
Elimination half-life	8 hours (6–10 hours)
Duration of action	~8 hours (50 mg)
Excretion	Feces: ~57%; Urine: ~28%
Identifiers
	IUPAC name [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone;
ECHA InfoCard	100.353.123
Chemical and physical data
Formula	C23H23ClN6O2
Molar mass	୪୫୦.୯୩ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl;
	InChI InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1; Key:NBGABHGMJVIVBW-QHCPKHFHSA-N;

ଡାରିଡୋରେକ୍ସାଣ୍ଟ, ଏକ ବିକ୍ରୟ ନାମ କ୍ୱିଭିଭିକ୍, ନିଦ୍ରାହୀନତାପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୩] ଯେଉଁମାନେ ଅତିକମରେ ତିନିମାସ ଧରି ଶୟନ ଅସୁବିଧାର ସମ୍ମୁଖୀନ ହେଉଥିବେ, ସେମାନଙ୍କ ପାଇଁ ଏହା ବ୍ୟବହୃତ ହୁଏ ଏବଂ କେବଳ ସ୍ୱଳ୍ପ ମିଆଦି ବ୍ୟବ‌ହାର ପାଇଁ ପରାମର୍ଶ ଦିଆଯାଏ ।^[୩] ଶୋଇବାର ଅଧ ଘଣ୍ଟା ପୂର୍ବରୁ ଏହାକୁ ପାଟିରେ ଦିଆଯାଏ ।^[୨]^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ନିଦ୍ରାଳି ଭାବ ଏବଂ ଥକାପଣ ହୋଇପାରେ ।^[୨] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅବସାଅଦ, ନିଦ୍ରା ପକ୍ଷାଘାତ ଏବଂ ଜଟିଳ ଶୋଇବା ଆଚରଣ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୨] ଏହାର ଅପବ୍ୟବହାର ହେବାର ସଙ୍କଟ ଅପେକ୍ଷାକୃତ କମ୍ ରହିଛି ।^[୨] ^[୫] ଯକୃତ ଜନିତ ସମସ୍ୟା କିମ୍ବା ନିଦ୍ରାବେଶରେଏହା ବ୍ୟବହାର କରିବା ଉଚିତ୍ ନୁହେଁ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବ‌ହାର ଜନିତ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ । ^[୧] ଏହା ଏକ ଡୁଆଲ୍ ଓରେକ୍ସିନ୍ ରିସେପ୍ଟର ଆଣ୍ଟାଗୋନିଷ୍ଟ (DORA) ଏବଂ ଓରେକ୍ସିନ କ୍ରିୟାକୁ ଅବରୋଧ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୩] ଏହା ଏକ ବେଞ୍ଜୋଡାଏଜେପିନ କିମ୍ବା ଜେଡ-ଡ୍ରଗ୍ ନୁହେଁ । ^[୬]

୨୦୨୨ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଡାରିଡୋରେକ୍ସାଣ୍ଟ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ମସିହାର ଏହାର ଏକ ମାସ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ୪୭୦ ଡଲାର ଖର୍ଚ୍ଚ ହୁଏ ।^[୭] ୨୦୨୨ ସୁଦ୍ଧା ବ୍ରିଟେନରେ ଏହା ବ୍ୟବସାୟିକ ଭାବରେ ଉପଲବ୍ଧ ହୋଇନାହିଁ ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ଏକ କାର୍ଯ୍ୟସୂଚୀ ଚତୁର୍ଥ ନିୟନ୍ତ୍ରିତ ପଦାର୍ଥ ।^[୨]

ଆଧାର

1 2 "Daridorexant Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 10 December 2022.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Quviviq- daridorexant tablet, film coated". DailyMed. 23 March 2022. Archived from the original on 19 September 2022. Retrieved 18 September 2022.
1 2 3 4 5 6 "Quviviq EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 4 May 2022. Retrieved 5 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1 2 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opin Drug Metab Toxicol. 16 (11): 1063–1078. doi:10.1080/17425255.2020.1817380. PMID 32901578. S2CID 221572078.
↑ "Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV". Archived from the original on 13 April 2022. Retrieved 13 April 2022.
↑ Roch C, Bergamini G, Steiner MA, Clozel M (October 2021). "Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia". Psychopharmacology (Berl). 238 (10): 2693–2708. doi:10.1007/s00213-021-05954-0. PMC 8455402. PMID 34415378.
↑ "Daridorexant". Retrieved 10 December 2022.
↑ "Daridorexant". SPS - Specialist Pharmacy Service. 13 April 2019. Archived from the original on 17 May 2022. Retrieved 10 December 2022.

[AHFS2022-1] 1 2 "Daridorexant Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 10 December 2022.

[PI2022-2] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Quviviq- daridorexant tablet, film coated". DailyMed. 23 March 2022. Archived from the original on 19 September 2022. Retrieved 18 September 2022.

[EPAR2022-3] 1 2 3 4 5 6 "Quviviq EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 4 May 2022. Retrieved 5 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[pmid32901578-4] 1 2 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opin Drug Metab Toxicol. 16 (11): 1063–1078. doi:10.1080/17425255.2020.1817380. PMID 32901578. S2CID 221572078.

[FederalRegister2022-5] "Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV". Archived from the original on 13 April 2022. Retrieved 13 April 2022.

[Roc2021-6] Roch C, Bergamini G, Steiner MA, Clozel M (October 2021). "Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia". Psychopharmacology (Berl). 238 (10): 2693–2708. doi:10.1007/s00213-021-05954-0. PMC 8455402. PMID 34415378.

[Rx2022-7] "Daridorexant". Retrieved 10 December 2022.

[SPS2022-8] "Daridorexant". SPS - Specialist Pharmacy Service. 13 April 2019. Archived from the original on 17 May 2022. Retrieved 10 December 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]